Search

Your search keyword '"Oliveira, Mafalda"' showing total 7 results
Start Over Author "Oliveira, Mafalda" Journal nature communications
7 results on '"Oliveira, Mafalda"'

1. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Author

Brasó-Maristany, Fara, Ferrero-Cafiero, Juan Manuel, Falato, Claudette, Martínez-Sáez, Olga, Cejalvo, Juan Miguel, Margelí, Mireia, Tolosa, Pablo, Salvador-Bofill, Francisco Javier, Cruz, Josefina, González-Farré, Blanca, Sanfeliu, Esther, Òdena, Andreu, Serra, Violeta, Pardo, Francisco, Luna Barrera, Ana María, Arumi, Miriam, Guerra, Juan Antonio, Villacampa, Guillermo, Sánchez-Bayona, Rodrigo, Ciruelos, Eva, Espinosa-Bravo, Martín, Izarzugaza, Yann, Galván, Patricia, Matito, Judith, Pernas, Sonia, Vidal, Maria, Santhanagopal, Anu, Sellami, Dalila, Esker, Stephen, Fan, Pang-Dian, Suto, Fumitaka, Vivancos, Ana, Pascual, Tomás, Prat, Aleix, and Oliveira, Mafalda

Published
2024
Full Text
View/download PDF

2. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

Author

Prat, Aleix, Brasó-Maristany, Fara, Martínez-Sáez, Olga, Sanfeliu, Esther, Xia, Youli, Bellet, Meritxell, Galván, Patricia, Martínez, Débora, Pascual, Tomás, Marín-Aguilera, Mercedes, Rodríguez, Anna, Chic, Nuria, Adamo, Barbara, Paré, Laia, Vidal, Maria, Margelí, Mireia, Ballana, Ester, Gómez-Rey, Marina, Oliveira, Mafalda, Felip, Eudald, Matito, Judit, Sánchez-Bayona, Rodrigo, Suñol, Anna, Saura, Cristina, Ciruelos, Eva, Tolosa, Pablo, Muñoz, Montserrat, González-Farré, Blanca, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., and Vivancos, Ana

Published
2023
Full Text
View/download PDF

3. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Author

Palafox, Marta, Monserrat, Laia, Bellet, Meritxell, Villacampa, Guillermo, Gonzalez-Perez, Abel, Oliveira, Mafalda, Brasó-Maristany, Fara, Ibrahimi, Nusaibah, Kannan, Srinivasaraghavan, Mina, Leonardo, Herrera-Abreu, Maria Teresa, Òdena, Andreu, Sánchez-Guixé, Mònica, Capelán, Marta, Azaro, Analía, Bruna, Alejandra, Rodríguez, Olga, Guzmán, Marta, Grueso, Judit, Viaplana, Cristina, Hernández, Javier, Su, Faye, Lin, Kui, Clarke, Robert B., Caldas, Carlos, Arribas, Joaquín, Michiels, Stefan, García-Sanz, Alicia, Turner, Nicholas C., Prat, Aleix, Nuciforo, Paolo, Dienstmann, Rodrigo, Verma, Chandra S., Lopez-Bigas, Nuria, Scaltriti, Maurizio, Arnedos, Monica, Saura, Cristina, and Serra, Violeta

Published
2022
Full Text
View/download PDF

4. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Author

Palafox, Marta, Monserrat, Laia, Bellet, Meritxell, Villacampa, Guillermo, Gonzalez-Perez, Abel, Oliveira, Mafalda, Brasó-Maristany, Fara, Ibrahimi, Nusaibah, Kannan, Srinivasaraghavan, Mina, Leonardo, Herrera-Abreu, Maria Teresa, Òdena, Andreu, Sánchez-Guixé, Mònica, Capelán, Marta, Azaro, Analía, Bruna, Alejandra, Rodríguez, Olga, Guzmán, Marta, Grueso, Judit, Viaplana, Cristina, Hernández, Javier, Su, Faye, Lin, Kui, Clarke, Robert B., Caldas, Carlos, Arribas, Joaquín, Michiels, Stefan, García-Sanz, Alicia, Turner, Nicholas C., Prat, Aleix, Nuciforo, Paolo, Dienstmann, Rodrigo, Verma, Chandra S., Lopez-Bigas, Nuria, Scaltriti, Maurizio, Arnedos, Monica, Saura, Cristina, and Serra, Violeta

Published
2022
Full Text
View/download PDF

5. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Author

Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, and Prat, Aleix

Published
2020
Full Text
View/download PDF

6. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.

Author

Palafox, Marta, Monserrat, Laia, Bellet, Meritxell, Villacampa, Guillermo, Gonzalez-Perez, Abel, Oliveira, Mafalda, Brasó-Maristany, Fara, Ibrahimi, Nusaibah, Kannan, Srinivasaraghavan, Mina, Leonardo, Herrera-Abreu, Maria Teresa, Òdena, Andreu, Sánchez-Guixé, Mònica, Capelán, Marta, Azaro, Analía, Bruna, Alejandra, Rodríguez, Olga, Guzmán, Marta, Grueso, Judit, and Viaplana, Cristina

Subjects
CYCLIN-dependent kinase inhibitors, ESTROGEN receptors, BREAST cancer, METASTATIC breast cancer, HORMONE therapy, CANCER patients, P16 gene
Abstract

CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Author

De Mattos-Arruda, Leticia, primary, Mayor, Regina, additional, Ng, Charlotte K. Y., additional, Weigelt, Britta, additional, Martínez-Ricarte, Francisco, additional, Torrejon, Davis, additional, Oliveira, Mafalda, additional, Arias, Alexandra, additional, Raventos, Carolina, additional, Tang, Jiabin, additional, Guerini-Rocco, Elena, additional, Martínez-Sáez, Elena, additional, Lois, Sergio, additional, Marín, Oscar, additional, de la Cruz, Xavier, additional, Piscuoglio, Salvatore, additional, Towers, Russel, additional, Vivancos, Ana, additional, Peg, Vicente, additional, Ramon y Cajal, Santiago, additional, Carles, Joan, additional, Rodon, Jordi, additional, González-Cao, María, additional, Tabernero, Josep, additional, Felip, Enriqueta, additional, Sahuquillo, Joan, additional, Berger, Michael F., additional, Cortes, Javier, additional, Reis-Filho, Jorge S., additional, and Seoane, Joan, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results